BioMarin Pharma (BMRN) Tops Q3 EPS by 5c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioMarin Announces Third Quarter 2015 Financial Results and Company Update
October 29, 2015 4:03 PM EDT- Vimizim Net Product Revenue $65 million in the Quarter; Vimizim Full-year Revenue Guidance Increased to $220 to $235 million
- Full-year Total BioMarin Revenue Guidance Increased to $880 million to $900 million
- FDA Advisory Committee to Review Kyndrisa (drisapersen) November 24th for Treatment of Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Financial Highlights ($ in millions, except per share data, unaudited)Â
 Three MonthsEnded September... More